Last reviewed · How we verify
Bendamustine and Rituximab
Bendamustine is a chemotherapy medication that interferes with DNA replication, while Rituximab is a monoclonal antibody that targets and depletes B cells.
Bendamustine is a chemotherapy medication that interferes with DNA replication, while Rituximab is a monoclonal antibody that targets and depletes B cells. Used for Chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | Bendamustine and Rituximab |
|---|---|
| Also known as | Mabthera, Levact |
| Sponsor | Czech CLL Study Group |
| Drug class | Chemotherapy, Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bendamustine works by causing cross-links in DNA, which prevents cancer cells from replicating. Rituximab binds to CD20 on B cells, marking them for destruction by the immune system. This combination is used to treat certain types of non-Hodgkin lymphoma.
Approved indications
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
- CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma (PHASE1)
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |